Theme > Industry > Healthcare > Immuno>Oncology

Analyst Comment

ESMO 2025: Hengrui’s immunotherapy combo shows perioperative benefit in HCC

The results strengthen Hengrui’s dominance in the Chinese market, showing camrelizumab and rivoceranib's potential beyond advanced disease.

GlobalData Healthcare

Analyst Comment

ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC

Analyst Comment

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Analyst Comment

IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma

Analyst Comment

PD-1 inhibitors and systemic oncolytic viral immunotherapies under the spotlight at IO360

Data Insights

Immuno-oncology: the leading companies in oncolytic viruses revealed

Data Insights

Immuno-oncology: the leading companies in oncolytic adenovirus vectors revealed

Data Insights

Immuno-oncology: the leading companies in neoepitope prediction revealed

Data Insights

Leading innovators in PDK-1 inhibitors for the pharmaceutical industry

Data Insights

Immuno-oncology: the leading companies in cancer immunotherapy revealed

Data Insights

Immuno-oncology: the leading companies in immunotherapy radiotherapy combination revealed

Features

Subcutaneous drugs grant a new lease on life to checkpoint inhibitors

Phalguni Deswal

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close